All Updates

All Updates

icon
Filter
M&A
AiBtl BioPharma acquires TT Life Company to broaden precision product portfolio
Precision Medicine
Apr 18, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 18, 2024

AiBtl BioPharma acquires TT Life Company to broaden precision product portfolio

M&A

  • AiBtl BioPharma, ABVC BioPharma's subsidiary, has acquired precision medicine manufacturer TT Life Company by purchasing 1.66 million shares priced at USD 5.00 per share, valuing the deal at around USD 8.33 million. This also includes acquiring the Malaysian import trading company, direct sales company, and Taiwanese direct sales company.

  • The acquisition is anticipated to leverage TT Life Company's expertise in product design and manufacturing to generate synergies across R&D, manufacturing, distribution, and financial capabilities, potentially enabling AiBtl to launch a wide array of AI-driven precision medicine.

  • AiBtl BioPharma is a biopharmaceutical company engaged in the development of novel therapies for central nervous system disorders, including major depressive disorder (MDD) and ADHD. The company's approach involves utilizing plant-based norepinephrine transporter inhibitors, currently in clinical development stages. One drug is in Phase IIb trials, and another has completed Phase II and is moving towards Phase III. AiBtl BioPharma operates from the United States and has significant activities in Asia, including clinical trials conducted in Cambodia, Thailand, and Japan.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.